Older adolescents and very young adults with Hodgkin lymphoma appear to have better outcomes when treated with a pediatric trial protocol than similarly-aged patients treated with an adult trial protocol, according to a study involving >500 individuals. Participants were between 17 and 21 years of age and had Hodgkin lymphoma. They were treated as part of either the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult study (n=114) or the pediatric Children's Oncology Group study (n=391). Investigators looked at failure-free and overall survival. Among the results:
- The 5-year failure-free and overall survival rates were 68% and 89%, respectively, in the adult trial and 81% and 97%, respectively, in the pediatric study.
- All subgroups treated in the adult trial had worse failure-free survival except for patients with stages 1 or 2 lymphoma without anemia.
- Younger patients treated in the adult trial group had worse failure-free survival than 22- to 44-year-olds treated in the same trial.
- Outcomes were similar regardless of age in the pediatric trial.
Henderson T, Parsons S, Wroblewski K, et al. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. [Published online ahead of print September 13, 2017]. Cancer. doi:10.1002/cncr.30979.